How Testosterone Cypionate Affects Total Testosterone Levels

Mechanism: How Cypionate Ester Delivers Testosterone

Testosterone cypionate is testosterone bound to a cyclopentylpropionate ester, dissolved in cottonseed oil for intramuscular depot injection. Once injected into muscle tissue, the oil depot slowly releases testosterone cypionate into surrounding tissue. Esterases in the bloodstream then cleave the cypionate ester from the testosterone molecule, liberating free testosterone into circulation.

This free testosterone is identical to endogenously produced testosterone. It binds sex hormone-binding globulin (SHBG) and albumin in the same proportions as native hormone, contributing directly to the total testosterone measurement on standard immunoassay or LC-MS/MS testing 1. The cypionate ester confers a terminal half-life of approximately 8 days, which is why clinicians prescribe it on weekly or biweekly schedules.

Total testosterone measured by blood draw reflects both exogenous (injected) and any residual endogenous production. Within weeks of starting TRT, hypothalamic-pituitary feedback suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), effectively shutting down testicular testosterone synthesis 2. The measured total testosterone on therapy therefore represents almost entirely the exogenous supply.

Magnitude of Increase: What the Data Shows

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with total testosterone below 275 ng/dL, provide the most rigorous efficacy data for testosterone gel. However, injectable cypionate produces comparable steady-state levels when dosed appropriately 1.

In the TTrials, men randomized to testosterone achieved mean total testosterone levels of 565 ng/dL at 3 months versus a baseline mean of approximately 232 ng/dL. That represents a 143% increase from baseline. Placebo-treated men showed no meaningful change 1.

For intramuscular testosterone cypionate specifically, pharmacokinetic studies demonstrate that 200 mg administered every 2 weeks produces peak levels of approximately 1,000-1 to 200 ng/dL at 48-72 hours post-injection, falling to trough values of 300-500 ng/dL by day 14 3. Weekly injections of 100 mg produce more stable kinetics: peaks of 700-900 ng/dL and troughs of 500-700 ng/dL. A pharmacokinetic modeling study published in the Journal of Clinical Endocrinology & Metabolism confirmed that splitting the biweekly dose into weekly administration reduces the peak-to-trough ratio from approximately 2.5:1 down to 1.5:1 3.

Time Course: From First Injection to Steady State

The pharmacokinetic profile of testosterone cypionate follows predictable accumulation kinetics. After a single 100 mg intramuscular injection, total testosterone peaks at 48-72 hours, then declines with the 8-day half-life of the cypionate ester.

With repeated dosing, accumulation occurs over approximately 4-5 half-lives. For an 8-day half-life compound on a 7-day dosing interval, this translates to steady state at roughly 4-6 weeks 4. Labs drawn before this point will underestimate the eventual steady-state trough.

The Endocrine Society Clinical Practice Guideline (2018) recommends measuring total testosterone 4-6 weeks after initiation, then adjusting dose to achieve a trough in the mid-normal range of 450-600 ng/dL 4. The guideline states: "For testosterone cypionate or enanthate, measure testosterone midway between injections. The target is a testosterone level in the mid-normal range (450-600 ng/dL)."

A practical timeline looks like this: Week 1 shows initial elevation but no steady state. Week 2-3 shows rising troughs as drug accumulates. Week 4-6 achieves approximate steady state. Labs drawn at week 6 reliably reflect the patient's long-term total testosterone on that dose.

Dose-Response Relationship

Total testosterone response to testosterone cypionate is approximately linear across the therapeutic dose range, though individual variation is substantial due to differences in injection site absorption, SHBG levels, body composition, and metabolic clearance rate.

A dose-finding study by Bhasin et al. assigned healthy young men to graded doses of testosterone enanthate (pharmacokinetically interchangeable with cypionate) after suppressing endogenous production with a GnRH agonist. Results demonstrated clear dose-response: 25 mg/week produced mean total testosterone of approximately 253 ng/dL, 50 mg/week yielded 306 ng/dL, 125 mg/week reached 570 ng/dL, 300 mg/week achieved 1 to 345 ng/dL, and 600 mg/week pushed levels to 2 to 370 ng/dL 5.

These data confirm that typical TRT doses of 75-100 mg weekly place most men in the 500-700 ng/dL range at trough. The American Urological Association (AUA) guideline defines the normal range as 300-1 to 000 ng/dL and recommends targeting the mid-normal range during TRT 6.

Doses exceeding 150 mg weekly frequently produce supraphysiologic total testosterone (above 1,000-1 to 100 ng/dL), which increases erythrocytosis risk without proportional symptomatic benefit for most patients 4.

Peak-Trough Variability and Its Clinical Relevance

One characteristic of injectable testosterone cypionate that distinguishes it from gels or pellets is the sawtooth pharmacokinetic pattern. Each injection creates a peak followed by a gradual decline to trough. Patients often report symptom fluctuation that correlates with this cycle.

On a every-two-week protocol (200 mg every 14 days), the peak-to-trough ratio can exceed 3:1. A man whose peak reaches 1 to 200 ng/dL at day 2 may drop to 350-400 ng/dL by day 14. This large swing means total testosterone spends time both above and below the target range during each cycle 3.

Weekly injections of half the biweekly dose (100 mg every 7 days) reduce this variability substantially. The trough on a weekly protocol typically remains above 500 ng/dL, and the peak stays below 900 ng/dL 7. Some clinicians prescribe twice-weekly injections (e.g., 50 mg every 3.5 days) to further flatten the curve, producing near-constant total testosterone in the 550-700 ng/dL range.

The Endocrine Society does not mandate a specific injection frequency but acknowledges that more frequent dosing reduces peak-trough swings and may improve symptom stability and reduce hematocrit elevation 4.

Monitoring Protocol: When and How to Check Total Testosterone

Correct timing of blood draws is essential for meaningful interpretation. The 2018 Endocrine Society guideline and the AUA 2018 guideline both specify measuring total testosterone at trough, defined as the lowest point in the dosing cycle 4 6.

For weekly injections: draw blood on the morning of injection day, before administering the dose. This captures the true trough. For biweekly injections: draw blood on day 13 or 14 (the day before or the day of the next injection). For twice-weekly injections: draw on the morning of either injection day, before the dose.

Drawing blood at peak (24-72 hours post-injection) will overestimate the patient's functional testosterone status and may trigger unnecessary dose reductions. Drawing mid-cycle provides intermediate information but lacks standardization.

The recommended monitoring schedule from the Endocrine Society 4 is:

First check at 4-6 weeks after starting or changing dose. Second check at 3 months if dose adjustment was made. Then every 6-12 months once stable. If trough total testosterone is below 400 ng/dL, increase dose by 25-50 mg weekly. If above 700 ng/dL at trough, consider reducing dose unless clinical symptoms warrant higher levels and hematocrit remains below 54%.

Factors That Modify the Total Testosterone Response

Two men on identical testosterone cypionate doses can show different total testosterone levels. Several variables explain this:

SHBG concentration. Men with higher SHBG bind more testosterone, raising total testosterone but not necessarily free testosterone. Obesity, insulin resistance, and type 2 diabetes lower SHBG, meaning total testosterone may appear lower even when free testosterone is adequate 8.

Body mass index. Higher body fat increases the volume of distribution for testosterone and accelerates aromatization to estradiol. Obese men on TRT often require higher doses to achieve the same total testosterone compared to lean men 5.

Injection technique and site. Subcutaneous injection of testosterone cypionate produces bioequivalent steady-state total testosterone compared to intramuscular injection, with some studies suggesting slightly lower peak levels and reduced variability 7. Depth of injection, muscle group used, and even ambient temperature at the injection site can affect absorption rate.

Concurrent medications. Aromatase inhibitors (anastrozole) reduce conversion of testosterone to estradiol, which can slightly increase total testosterone. 5-alpha reductase inhibitors (finasteride, dutasteride) do not meaningfully alter total testosterone levels 9.

Does Testosterone Cypionate Ever Lower Total Testosterone?

This question seems paradoxical, but context matters. In men with normal baseline testosterone who receive exogenous testosterone cypionate, the exogenous supply suppresses LH and FSH within 2-3 weeks. If the exogenous dose is insufficient to replace what the testes were producing, total testosterone could theoretically decrease during the transition period.

In clinical practice, this scenario is rare because standard starting doses (100 mg weekly) exceed most men's endogenous daily production of 4-7 mg. The more common scenario where total testosterone appears to drop occurs when: a patient is non-adherent to the injection schedule, the injection technique results in poor absorption (subcutaneous leak or depot failure), or labs are drawn at an unexpected time relative to the injection.

After discontinuing testosterone cypionate, total testosterone will fall as the exogenous supply clears (over 4-6 weeks) and endogenous production may take 2-6 months to recover fully, depending on duration of prior TRT and individual hypothalamic-pituitary-gonadal axis resilience 10.

Comparing Total Testosterone Outcomes Across TRT Formulations

Testosterone cypionate is not the only TRT formulation, and patients often ask how total testosterone levels compare across delivery systems.

Testosterone enanthate is pharmacokinetically interchangeable with cypionate. Both use similar ester chain lengths (cypionate has a cyclopentyl group; enanthate has a heptanoate chain), producing nearly identical half-lives and peak-trough profiles 3.

Transdermal testosterone (gels, patches) produces flatter kinetics with lower peaks but requires daily application. Mean total testosterone on 1% gel (50-100 mg daily application) typically reaches 500-700 ng/dL without the sawtooth pattern 1.

Testosterone undecanoate (Aveed) is a long-acting injectable with a half-life of approximately 34 days. After a loading period, injections every 10 weeks produce very stable total testosterone in the 400-600 ng/dL range with minimal peak-trough variation 4.

Subcutaneous testosterone pellets (Testopel) provide 3-6 months of release, with total testosterone peaking in the first month and gradually declining. Many men experience end-of-cycle symptoms as levels fall below target.

The choice between formulations depends on patient preference for injection frequency, tolerance of fluctuation, and cost. Testosterone cypionate remains the most commonly prescribed injectable in the United States due to its low cost (~$30-60/month without insurance), flexible dosing, and well-characterized pharmacokinetics.

Clinical Significance of Reaching Target Total Testosterone

Achieving and maintaining total testosterone in the mid-normal range correlates with the clinical benefits demonstrated in the TTrials and subsequent studies. In the TTrials, men who achieved mean total testosterone of 565 ng/dL showed statistically significant improvements in sexual function (Sexual Activity domain increased by 0.58 on a 12-point scale, P<0.001), physical function (6-minute walk distance increased by 6.0 meters, P=0.04), and mood (PHQ-9 depression scores improved) compared to placebo 1.

The TRAVERSE trial (N=5,246), a cardiovascular safety trial published in 2023, confirmed that maintaining total testosterone in the normal range with topical testosterone did not increase major adverse cardiovascular events (HR 0.99 to 95% CI 0.81-1.21) over a mean follow-up of 33 months 11.

These data support the Endocrine Society's recommendation to titrate testosterone cypionate to achieve a trough total testosterone of 450-600 ng/dL 4. Levels consistently below 400 ng/dL at trough suggest under-dosing. Levels consistently above 1 to 000 ng/dL at trough indicate excess dosing and warrant reduction to minimize polycythemia and other dose-dependent adverse effects.

Measure trough total testosterone at 6 weeks post-initiation, target 450-600 ng/dL, and adjust by 25 mg weekly increments until the patient achieves both biochemical and symptomatic goals.